Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Theravance Biopharma Stock Is Tanking Today

By Cory Renauer – Aug 24, 2021 at 3:02PM

Key Points

  • A phase 2 trial with an ulcerative colitis candidate failed to meet its primary endpoint.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's second clinical-trial flop in as many months isn't sitting well with investors.

What happened

The stock of Theravance Biopharma (TBPH -0.86%) is losing ground after a phase 2 trial failed to meet its primary endpoint. Investors disappointed with the company's mid-stage pipeline asset sent the stock down 34.4% as of 2:28 p.m. EDT on Tuesday.

So what 

Sales of Theravance Biopharma's commercial-stage drugs aren't strong enough yet to make ends meet. Investors hoping izencitinib can become a blockbuster treatment that bridges the gap were met with disappointment today.

Physician taking notes in a hospital room.

Image source: Getty Images.

The company read out results from a phase 2b trial with izencitinib, an oral treatment candidate for inflammatory bowel disease patients. Sadly, patients randomized to receive izencitinib didn't achieve significant improvement in disease severity compared to those who received a placebo. 

Theravance's inhaled antiviral candidate for the treatment of severe COVID-19 flopped in a phase 2 trial this June.

Now what

Theravance Biopharma is developing izencitinib in partnership with Johnson & Johnson (JNJ -0.70%). Under the terms of their deal, Theravance is still eligible to receive $900 million in milestone payments from izencitinib and other potential candidates to treat inflammation of the intestinal lining.

Today's flop in ulcerative colitis doesn't bode well for an ongoing phase 2 trial with Crohn's disease patients and izencitinib. The company expects to read out top-line Crohn's disease trial results around the end of 2021 or the beginning of 2022.

Theravance doesn't seem too enthusiastic about its izencitinib program and flat out told investors it would divert resources to more promising ventures. There's no shortage of options. For example, the company expects to read out top-line data from a phase 3 trial with ampreloxetine, a potential new treatment for neurogenic orthostatic hypotension before the end of September.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Theravance Biopharma Stock Quote
Theravance Biopharma
$10.40 (-0.86%) $0.09
Johnson & Johnson Stock Quote
Johnson & Johnson
$176.09 (-0.70%) $-1.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.